Universität zu Köln

Wolfsgruber, Steffen, Polcher, Alexandra, Koppara, Alexander, Kleineidam, Luca, Froelich, Lutz, Peters, Oliver, Huell, Michael, Ruether, Eckart, Wiltfang, Jens ORCID: 0000-0003-1492-5330, Maier, Wolfgang, Kornhuber, Johannes ORCID: 0000-0002-8096-3987, Lewczuk, Piotr, Jessen, Frank and Wagner, Michael ORCID: 0000-0003-2589-6440 (2017). Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. J. Alzheimers Dis., 58 (3). S. 939 - 951. AMSTERDAM: IOS PRESS. ISSN 1875-8908

Full text not available from this repository.

Abstract

Background: There is very limited data on the prevalence of abnormal cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) and their predictive value for clinical progression in memory clinic patients with subjective cognitive decline (SCD). Objective: To assess the frequency of abnormal CSF biomarkers of AD and their predictive value for clinical progression in memory clinic patients with SCD in comparison to patients with mild cognitive impairment (MCI) from the same cohort. Methods: We analyzed prospective data from memory clinic patients of the German Competence Network Dementia cohort with a baseline diagnosis of SCD (n = 82) or MCI (n = 134), distinguished by actuarial neuropsychological MCI criteria ( Jak-Bondi criteria). Risk of clinical progression during 3-year follow-up was evaluated with Cox-Proportional-Hazard models. Results: Prevalence of abnormal values in CSF markers of tau-mediated neurodegeneration (67.8% versus 46.3%) but not of amyloid deposition (40.3% versus 35.4%) was significantly higher in MCI compared to SCD. The rate of incident AD dementia (26.1% versus 12.2%) was also significantly higher in MCI. In SCD, additional 22% progressed to MCI during follow-up. Combined amyloid/tau abnormality was the strongest predictor of clinical progression in both groups. Conclusion: High prevalence of biomarker abnormality and clinical progression, together with the predictive value of CSF biomarkers, in memory clinic patients with SCD support the validity and usefulness of this condition as a pre-MCI at risk stage of AD.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Wolfsgruber, Steffen UNSPECIFIED UNSPECIFIED UNSPECIFIED Polcher, Alexandra UNSPECIFIED UNSPECIFIED UNSPECIFIED Koppara, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Kleineidam, Luca UNSPECIFIED UNSPECIFIED UNSPECIFIED Froelich, Lutz UNSPECIFIED UNSPECIFIED UNSPECIFIED Peters, Oliver UNSPECIFIED UNSPECIFIED UNSPECIFIED Huell, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Ruether, Eckart UNSPECIFIED UNSPECIFIED UNSPECIFIED Wiltfang, Jens UNSPECIFIED orcid.org/0000-0003-1492-5330 UNSPECIFIED Maier, Wolfgang UNSPECIFIED UNSPECIFIED UNSPECIFIED Kornhuber, Johannes UNSPECIFIED orcid.org/0000-0002-8096-3987 UNSPECIFIED Lewczuk, Piotr UNSPECIFIED UNSPECIFIED UNSPECIFIED Jessen, Frank UNSPECIFIED UNSPECIFIED UNSPECIFIED Wagner, Michael UNSPECIFIED orcid.org/0000-0003-2589-6440 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-243550
DOI:	10.3233/JAD-161252
Journal or Publication Title:	J. Alzheimers Dis.
Volume:	58
Number:	3
Page Range:	S. 939 - 951
Date:	2017
Publisher:	IOS PRESS
Place of Publication:	AMSTERDAM
ISSN:	1875-8908
Language:	English
Faculty:	Faculty of Management, Economy and Social Sciences
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PRECLINICAL ALZHEIMERS-DISEASE; NEUROPSYCHOLOGICAL ASSESSMENT; AMYLOID PATHOLOGY; DEMENTIA; CSF; PREVALENCE; COHORT; CONSORTIUM; COMPLAINTS; A-BETA-42 Multiple languages Neurosciences Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/24355